Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ADITYA H GAUR

Allopathic & Osteopathic Physicians Pediatrics Pediatric Infectious Diseases

NPI
1124021258
CMS profile
322624
Location
MEMPHIS, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,220.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,220.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
ViiV Healthcare Company $3,220.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ADITYA H GAUR

NPI 1124021258 · CMS profile ID 322624

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Infectious Diseases

MEMPHIS, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124021258?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ADITYA H GAUR, NPI 1124021258, CMS profile ID 322624. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124021258?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ADITYA H GAUR, NPI 1124021258, CMS profile ID 322624. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124021258?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ADITYA H GAUR, NPI 1124021258, CMS profile ID 322624, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1124021258?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $3,220.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ViiV Healthcare Company $3,220.0012/14/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803262457 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $3,220.00 1
PY2023 $105.33 1
PY2024 $3,948.91 12
PY2025 $1,745.30 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $30,992.64 25
PY2024 Principal investigator $109,202.34 31
PY2023 Principal investigator $49,580.00 24
PY2022 Principal investigator $325,385.33 16
PY2021 Principal investigator $628,189.72 22
PY2020 Principal investigator $146,539.82 24
PY2019 Principal investigator $78,758.09 37

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Gilead Sciences, Inc. $1,201.00 12/18/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676395325
Principal investigator 1 Gilead Sciences, Inc. $830.00 11/20/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 676395311
Principal investigator 1 Gilead Sciences, Inc. $2,839.00 11/20/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676395317
Principal investigator 1 Gilead Sciences, Inc. $842.00 10/23/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children No dispute reported 06/30/2026 676395297
Principal investigator 1 Gilead Sciences, Inc. $1,744.00 10/23/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 676395301
Principal investigator 1 Gilead Sciences, Inc. $3,410.00 10/23/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676395305
Principal investigator 1 Gilead Sciences, Inc. $830.00 09/18/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 676395285
Principal investigator 1 Gilead Sciences, Inc. $3,410.00 09/18/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676395291
Principal investigator 1 ViiV Healthcare Company $234.31 09/06/2019 Non-covered Recipient Entity
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
PHASE I/II STUDY OF THE SAFETY, ACCEPTABILITY, TOLERABILITY, AND PHARM No dispute reported 06/30/2026 669628801
Principal investigator 1 Gilead Sciences, Inc. $437.00 08/21/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676395273
Principal investigator 1 Gilead Sciences, Inc. $2,346.00 08/21/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 676395281
Principal investigator 1 Gilead Sciences, Inc. $100.00 08/19/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children No dispute reported 06/30/2026 676395265
Principal investigator 1 Gilead Sciences, Inc. $664.00 07/17/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children No dispute reported 06/30/2026 676395257
Principal investigator 1 Gilead Sciences, Inc. $4,970.00 07/17/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676395261
Principal investigator 1 Gilead Sciences, Inc. $775.00 06/19/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children No dispute reported 06/30/2026 676395249
Principal investigator 1 Gilead Sciences, Inc. $3,456.00 06/19/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676395253
Principal investigator 1 Gilead Sciences, Inc. $437.00 05/22/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676395237
Principal investigator 1 Gilead Sciences, Inc. $775.00 05/22/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children No dispute reported 06/30/2026 676395244
Principal investigator 1 Gilead Sciences, Inc. $18.78 04/24/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 676395231
Principal investigator 1 Gilead Sciences, Inc. $225.00 04/22/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children No dispute reported 06/30/2026 676395221
Principal investigator 1 Gilead Sciences, Inc. $343.00 04/22/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofavir Alafenamide Single Tablet Regimen in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Surpressed Children No dispute reported 06/30/2026 676395225
Principal investigator 1 Gilead Sciences, Inc. $775.00 04/17/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children No dispute reported 06/30/2026 676395209
Principal investigator 1 Gilead Sciences, Inc. $3,847.00 04/17/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676395215
Principal investigator 1 Gilead Sciences, Inc. $761.00 03/20/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 676395191
Principal investigator 1 Gilead Sciences, Inc. $1,550.00 03/20/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children No dispute reported 06/30/2026 676395197
Principal investigator 1 Gilead Sciences, Inc. $2,929.00 03/20/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676395203
Principal investigator 1 Gilead Sciences, Inc. $830.00 02/20/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 676395171
Principal investigator 1 Gilead Sciences, Inc. $2,600.00 02/20/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofavir Alafenamide Single Tablet Regimen in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Surpressed Children No dispute reported 06/30/2026 676395178
Principal investigator 1 Gilead Sciences, Inc. $10,131.00 02/20/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676395185
Principal investigator 1 Gilead Sciences, Inc. $675.00 01/30/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children No dispute reported 06/30/2026 676395159
Principal investigator 1 Gilead Sciences, Inc. $746.00 01/28/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofavir Alafenamide Single Tablet Regimen in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Surpressed Children No dispute reported 06/30/2026 676395141
Principal investigator 1 Gilead Sciences, Inc. $1,800.00 01/28/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children No dispute reported 06/30/2026 676395145
Principal investigator 1 Gilead Sciences, Inc. $2,325.00 01/28/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children No dispute reported 06/30/2026 676395149
Principal investigator 1 Gilead Sciences, Inc. $12,702.00 01/28/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects No dispute reported 06/30/2026 676395153
Principal investigator 1 Gilead Sciences, Inc. $800.00 01/23/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults No dispute reported 06/30/2026 676395127
Principal investigator 1 Gilead Sciences, Inc. $1,800.00 01/23/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Open Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen No dispute reported 06/30/2026 676395133
Principal investigator 1 Gilead Sciences, Inc. $4,600.00 01/23/2019 Non-covered Recipient Entity
ST JUDE CHILDRENS RESEARCH HOSPITAL
A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants No dispute reported 06/30/2026 676395137